Ahmet Dirican, Professor of Medical Oncology at Medicana International İzmir Hospital, shared a post on X:
“Precision oncology dilemma Metastatic melanoma NGS: BRAF V600E + PTEN mutation Guidelines would say: BRAF + MEK inhibitors.
But is that really enough?
PTEN loss is known to activate the PI3K/AKT pathway and may drive resistance to BRAF-targeted therapy.
So the real question:
- Are we still treating a single mutation, while the tumor biology is already more complex?
- Should cases like this push us toward smarter combination strategies?
- What would you do?”
Other articles about Metastatic Melanoma on OncoDaily.
